Skip to main content
. 2023 May 22;10:1192093. doi: 10.3389/fcvm.2023.1192093

Table 1.

Baseline demographics and clinical features stratified according to RCA PCAT attenuation.

Patient characteristics at study baseline RCA PCAT attenuation >−70.5 (n = 20) RCA PCAT attenuation ≤−70.5 (n = 42) P-value
Age, years 83.9 ± 6.0 81.4 ± 6.9 0.23
Female (%) 7 (35.0) 20 (47.6) 0.35
BMI, kg/m² 27.7 ± 5.3 31.5 ± 7.3 0.005
Medical history, n (%)
Hypertension 16 (80.0) 32 (76.2) 0.74
Atrial fibrillation 9 (45.0) 19 (45.2) 0.99
Stroke or TIA 2 (10.0) 3 (7.1) 0.72
Diabetes mellitus 9 (45.0) 16 (38.1) 0.60
Peripheral vascular disease 2 (10.0) 5 (11.9 0.83
Cardiac assessment
NYHA class
I 0 1 (2.4) 0.49
II 4 (20.0) 10 (23.8) 0.74
III 12 (60.0) 30 (71.4) 0.37
IV 4 (20.0) 1 (2.4) 0.02
EuroSCORE II 5.1 (3.0–17.6) 2.4 (1.6–3.8) <0.001
Previously diagnosed CAD (%) 8 (40.0) 12 (28.6) 0.39
Clinical features
CRP, mg/L 0.5 (0.06–10.7) 0.3 (0.04–2.9) 0.474
Leukocytes, /µL 7.5 (5.9–9.0) 7.0 (5.0–7.7) 0.537
Troponin T, pg/mL 29.0 (15.5–54.5) 18.2 (14.7–25) 0.011
Creatinine, mg/dL 1.8 ± 1.4 1.0 ± 0.4 0.001
Receiving statin therapy, n (%) 16 (80.0) 27 (64.3) 0.21

The results are reported as n (%), mean ± SD, or median (range) as appropriate and rounded to the first decimal place. AU, arbitrary units; BMI, body mass index; stroke or TIA, transitory ischemic attack; NYHA class, New York Heart Association class; CAD, coronary artery disease; CRP, C-reactive protein.